Daniel S. Lorrain - Jan 31, 2025 Form 4 Insider Report for Contineum Therapeutics, Inc. (CTNM)

Role
Chief Scientific Officer
Signature
/s/ Peter Slover, Attorney-in-Fact
Stock symbol
CTNM
Transactions as of
Jan 31, 2025
Transactions value $
$0
Form type
4
Date filed
1/31/2025, 04:38 PM
Previous filing
Nov 27, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTNM Stock Option (right to buy) Award $0 +110K $0.00 110K Jan 31, 2025 Class A Common Stock 110K $9.79 Direct F1
transaction CTNM Stock Option (right to buy) Award $0 +3.7K $0.00 3.7K Jan 31, 2025 Class A Common Stock 3.7K $9.79 By Spouse F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options granted under the Issuer's 2024 Equity Incentive Plan (the "Plan"). 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's continuous service.
F2 Options granted under the Plan in connection with Reporting Person's spouse's continuous service at the Company. 25% of the option shares vest on January 1, 2026, and the remainder vests in equal monthly installments over the next 36 months thereafter, subject to the Reporting Person's spouse's continuous service.